Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Phase 1 Completed
62 enrolled
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
Phase 1 Completed
68 enrolled
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
Phase 1 Terminated
178 enrolled
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab
Phase 1 Completed
116 enrolled
Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Phase 1 Completed
72 enrolled
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors
Phase 1 Completed
43 enrolled
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
Phase 1 Completed
140 enrolled
Erlotinib in Combination With Cetuximab
Phase 1 Completed
65 enrolled
A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy
Phase 1 Withdrawn
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
Phase 1 Terminated
1 enrolled
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib
Phase 1 Withdrawn
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
Phase 1 Completed
15 enrolled
Study of Curcumin, Vorinostat, and Sorafenib
Phase 1 Withdrawn
Azacytidine and Valproic Acid in Patients With Advanced Cancers
Phase 1 Completed
69 enrolled
LY2275796 in Advanced Cancer
Phase 1 Completed
24 enrolled